SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla gains on the buzz of acquiring rights to market skin care products of Percos India

03 Sep 2015 Evaluate

Cipla is currently trading at Rs. 656.25, up by 6.20 points or 0.95% from its previous closing of Rs. 650.05 on the BSE.

The scrip opened at Rs. 655.30 and has touched a high and low of Rs. 662.40 and Rs. 655.10 respectively. So far 61076 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 752.45 on 10-Mar-2015 and a 52 week low of Rs. 546.00 on 05-Sep-2014.

Last one week high and low of the scrip stood at Rs. 688.75 and Rs. 640.35 respectively. The current market cap of the company is Rs. 52707.77 crore.

The promoters holding in the company stood at 36.79% while Institutions and Non-Institutions held 34.30% and 26.60% respectively.

Cipla, one of India’s leading generic pharmaceutical companies has reportedly acquired the exclusive rights to market skin care products of Percos India. This deal may be worth an estimated Rs 90 crore. The company will market few fast growing brands like Vedaderm, Claz, Actipeel, Tryses and Glycoveda, which have collective sales of around Rs 10 crore.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.



Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×